🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

At #ASH24, WCMHemOncFellow Dr. Gaurav Varma (Gaurav Varma) was involved with a study looking at the combination regimen P-GVAD in recurrent #HodgkinLymphoma: bit.ly/3BmSKd9

Dr. Erin Mulvey presented The Chemotherapy+ Foundation #CFS2024 on recent treatment advances in follicular #lymphoma, including BTK inhibitors and CAR T-cell therapy: bit.ly/4i1ZRs9 (cc: OncLive.com)

Watch Dr. Peter Martin discuss the role of Bruton’s tyrosine kinase (BTK) inhibitors for mantle cell #lymphoma with OncLive.com: bit.ly/3ZiRz6C

ICYMI: Dr. Erin Mulvey discussed the use of targeted therapies for the treatment of follicular #lymphoma and how these treatments have advanced care bit.ly/3ZkZiCs

Dr. John Allan recently spoke with CURE Today about understanding treatment options for relapsed/refractory chronic lymphocytic leukemia (#CLL): bit.ly/4g2uSdV

Hear from Dr. Peter Martin via OncLive.com on the role of Bruton’s tyrosine kinase (BTK) inhibitor-based combinations as the future of mantle cell #lymphoma (#MCL) treatment: bit.ly/41gYdNn

Join us on January 28, 2025, at 7:00 PM ET for an engaging conversation on global treatment strategies for Hodgkin lymphoma. MedNewsWeek Sarah Rutherford Wendy #HodgkinLymphoma #MedicalMentorship #WomenInMedicine Register now: ow.ly/qK2A50UFCXT

Watch Dr. Peter Martin discuss #PrecisionMedicine for the treatment of follicular #Lymphoma in this Clinical Care Options video and earn #CME credit: bit.ly/3PHJqo3

Presentation: onclive.com/view/comparing…

LISTEN: Dr. Jia Ruan participated in the VJHemOnc #podcast to discuss non-Hodgkin #Lymphoma updates from the 2024 @ASH_Hematology Annual Meeting bit.ly/3PYiGQ9

This year’s World Cancer Day theme is "United by Unique." Our collaborative approach to cancer care ensures patients receive top evaluations and therapies, including advancements in precision medicine and immune-based treatments. We make the fight against cancer personal.

Dr. Jia Ruan spoke with VJHemOnc about a phase 2 #ClinicalTrial evaluating a novel triplet combination for mantle cell #lymphoma (#MCL): bit.ly/4aHRNtt

#Lymphoma is unpredictable: you can’t control when it starts, how fast it grows, when it spreads to other organs, or who gets it. Mapped the next phase of our collab with #cancer #research pioneer Ari Melnick, a visionary #scientist & incredible mentor & collaborator for 12 yrs.

Watch Dr. Jia Ruan talk about long-term follow-up #ClinicalTrial combining azacitidine with CHOP #chemotherapy for previously untreated peripheral T-cell #lymphoma: bit.ly/3WK19yP (cc: VJHemOnc)

Drs. Sam Yamshon and Joshua Fein and other members of our #BMT team are at #Tandem2025 this week to share #research & learn about the latest in stem cell transplant, #CellularTherapy, and #GeneTherapy.

Dr. Richard Furman is speaking at the The Leukemia & Lymphoma Society Tri-State #BloodCancer Conference on April 5. This free in-person event brings together patients, loved ones, and healthcare professionals to discuss #research, treatment and survivorship. Register here: bit.ly/41d5SL4

Dr. Ari Melnick (Melnick Lab) was elected to the 2025 class of Fellows of the AACR Academy for his #research investigating epigenetic and transcriptional changes in #BloodCancers. Congratulations!

It’s not too late to register for the The Leukemia & Lymphoma Society Tri-State #BloodCancer Conference! Connect with those impacted by #Leukemia, #Lymphoma, #MultipleMyeloma and other blood cancers for a day of education. More details below.

Clinical research Weill Cornell Medicine NewYork-Presbyterian is dedicated to innovating, inspiring and transforming lives. On #ClinicalTrialsDay, some of our team members who support clinical research are sharing how we are Powered By Purpose. #CTD2025 ACRP - Assoc. of Clinical Research Profession

Dr. Sam Yamshon joined other #lymphoma experts to discuss two different CAR T-cell therapies and which patients are better suited for one vs the other: bit.ly/44WYRBA (cc: CancerNetwork®)